Can you elaborate on the significance of the 151 subjects enrolled in the SOL-1 pivotal study for AXPAXLI in wet AMD and what this indicates about the study's progress? 

What are the potential implications of the planned SOL-R study, which aims to evaluate repeat dosing of AXPAXLI in wet AMD, on future treatment protocols?

The 48-week HELIOS NPDR study results showed a 23.1% improvement in DRSS for patients in the AXPAXLI arm. How do these findings compare to existing treatments for diabetic retinopathy?

With no patients experiencing worsening of DRSS or vision-threatening complications in the AXPAXLI arm, how does this safety profile impact the potential adoption of AXPAXLI for wet AMD?

The SOL-1 study includes 60 active study sites and plans to enroll 300 treatment-naive patients. What challenges and opportunities do you see in achieving these enrollment targets?

The positive results from the HELIOS study showed no intraocular inflammation or other severe adverse effects. How important is this safety data in the context of developing new ophthalmic treatments?

How does AXPAXLI's mechanism of action and delivery method compare to other currently available treatments for wet AMD, and what advantages does it offer?

With Ocular Therapeutix's cash runway extending into 2028, how does the company's financial stability support the long-term development and commercialization of AXPAXLI and other pipeline products?